Citations

Mayo Clinic

Clear

21 citation(s) found for "Wright, Benjamin L".

OA07.2. Baseline Mucosal Impedance on High-Resolution Impedance Manometry Distinguishes Active From Inactive Eosinophilic Esophagitis
Martinez, Josealberto Arenas, Freeman, Catherine, Crowell, Michael, Vela, Marcelo, Wright, Benjamin, Horsley-Silva, Jennifer, Wang, Fangfang, Arenas-Martínez, Josealberto S., Freeman, Catherine , Crowell, Michael D. , Vela, Marcelo F. , Horsley‐Silva, Jennifer L.

Diseases of the Esophagus | August 22, 2026 | Volume: 39 | Issue: Supplement_1 | Pages: No page available

10.1093/dote/doag077.050 Get It

Abstract Topic Benign Disease: Eosinophilic Esophagitis Background Active inflammation in eosinophilic esophagitis (EoE) disrupts the mucosal barrier, leading to dilated intercellular spaces and decreased transepithelial electrical resistance. Mucosal impedance (MI) has been used to assess mucosal integrity in EoE. We evaluated whether baseline MI measured by high-resolution impedance manometry (HRIM) distinguishes active and inactive EoE. Methods We retrospectively reviewed data from patients with EoE who underwent endoscopic esophageal biopsies within three months of HRIM from 2018-2026 at our tertiary referral center and had no treatment changes between studies. We excluded patients with a history of foregut surgery, erosive esophagitis, or Barrett’s esophagus. Demographics, endoscopy and pathology results were collected by chart review. Active EoE was histologically defined as ≥15 eosinophils per high-power field. Esophageal baseline MI was measured in the 30-second landmark period for the whole esophagus (from 2 cm above LES to 2 cm below UES), distal esophagus (from 2–7 cm above LES), and mid/proximal esophagus (from 10 cm above LES to 2 cm below UES). Mann–Whitney U or T tests were used for comparisons . Optimal MI thresholds were identified by Youden index with 10,000 bootstrap validations, and interrater reliability was assessed using two-way mixed effects intraclass correlation coefficients. Results Seventy-three patients were included: 37 (51%) female, median age 52 years, median BMI 27.2 kg/m2. Fifty-seven patients (78%) had atopic history, including seasonal allergies (38, 52%), asthma (31, 42%), eczema (21, 29%), and food allergies (19, 26%). Thirty-nine patients (53%) were receiving proton pump inhibitors, 25 (34%) were not on EoE therapy, 5 (6.8%) were on swallowed topical steroids, 3 (4.1%) were on dupilumab, and 1 (1.4%) was on an elimination diet. Esophageal strictures were present in 23 patients (32%), and 45 (62%) had active EoE. Baseline MI measurement showed high interrater reliability (n=50, 2 raters; intraclass correlation coefficient 0.937–0.963, p<0.001). Basal mean and minimal impedance were significantly lower in active EoE across all segments, greatest in the distal esophagus (all p<0.05; Figure 1). ROC analysis showed high discrimination of distal mean MI, with a cutoff ≤1.91 kΩ (AUC=0.837, sensitivity 67.9%, specificity 86.7%, Youden 0.545; Figure 2). Conclusion Baseline mucosal impedance during HRIM distinguishes active from inactive EoE, with strongest discrimination in the distal esophagus, supporting MI as a potential, minimally-invasive physiologic marker of mucosal inflammation and disease activity. Clinically, MI may serve as an adjunct tool in dysphagia evaluation, prompting EoE-directed biopsy when abnormal, aiding management in biopsy–symptom discordance, and potentially supporting disease monitoring in selected patients. Larger prospective studies are warranted.
Detergent‐Containing Toothpaste Decreases Esophageal Mucosal Impedance and Alters Salivary Properties in Humans
Wright, Benjamin L., Crowell, Michael D., Luo, Huijun , Masuda, Mia Y., Itoh, Naohiro , Folmes, Karalyn, Stoa, Jean M., Buras, Matthew R., Sherman, Will, Baheti, Saurabh , Bowman, Dean, Hill, Lindsey C., Vela, Marcelo F. , Kita, Hirohito, Rank, Matthew A. , Horsley‐Silva, Jennifer L., Doyle, Alfred D. , Horsley-Silva, Jennifer L, Kita, H , Wright, Benjamin L. , Crowell, Michael D. , Masuda, Mia Y. , Stoa, Jeannie, Buras, Matthew, Kita, Hirohito , Hill, David B. , Horsley‐Silva, Jennifer L.

Allergy | July 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/all.70437 | PMID 42397127 Get It

ABSTRACT Background Eosinophilic esophagitis is associated with epithelial barrier dysfunction. Epidemiologic studies suggest environmental factors promote disease pathogenesis. The common household detergent sodium dodecyl sulfate (SDS) induces epithelial barrier dysfunction and eosinophilic inflammation in mice. We hypothesized that acute SDS exposure would compromise the esophageal mucosal barrier in humans. Methods Healthy adults brushed with 2 g of an SDS‐containing toothpaste. Esophageal impedance was measured continuously pre‐/post‐toothbrushing to assess the effect of toothpaste on epithelial barrier function. SDS was measured in saliva using a methylene blue anionic substances assay. Participants completed 1‐h esophageal string tests (ESTs) pre‐/post‐toothbrushing and protein isolates from EST eluates from the proximal and distal esophagus were analyzed by tandem mass tag mass spectrometry. Results Ten of twelve subjects completed the clinical study. SDS in the initial expectorate measured immediately after toothbrushing varied markedly (median: 321.40 μg/mL; range: 169.90–1243.00 μg/mL) and was detectable in saliva in 80% of subjects (median: 9.55 μg/mL; range: 0–123.40 μg/mL) at 60 min post toothbrushing. Esophageal mucosal impedance decreased within 30 min of toothbrushing ( p < 0.01). Toothbrushing increased salivary viscosity and proteins associated with mucosal defense in EST eluates. The tight junction pathway was downregulated while the salivary secretion and complement and coagulation cascades pathways were upregulated in the proximal esophagus. Conclusion In healthy individuals, SDS remained detectable in saliva for a prolonged period after toothbrushing at concentrations previously shown to disrupt esophageal epithelial barrier function in vitro. Toothbrushing with an SDS‐containing toothpaste was associated with reduced esophageal mucosal impedance, altered salivary properties, and activated mucosal immune responses.
Unraveling B Cell Lymphoma Presenting as AKI and Hypercalcemia in a Patient with BACH2 Variant and CVID
Wonnaparhown, Alex , Wright, Benjamin, Crawford, Renee, Wright, Benjamin

Journal of Human Immunity | May 1, 2026 | Volume: 2 | Issue: CIS2026 | Pages: No page available

10.70962/cis2026abstract.110 Get It

Introduction BACH2-related immunodeficiency and autoimmunity (BRIDA) increases the risk of developing B cell lymphoma. We present a case of a patient with a known history of common variable immunodeficiency (CVID) and BACH2 variant of uncertain significance, presenting with hypercalcemia and acute kidney injury (AKI), found to have T cell histiocyte-rich large B cell lymphoma of the spleen. Case Description 46-year-old male with CVID-like clinical picture with variant of uncertain significance in BACH2 (Combined Annotation Dependent Depletion [CADD] 25.2, allele frequency 2) and granulomatous-lymphocytic interstitial lung disease (GL-ILD), admitted for acute kidney injury with hypercalcemia. He is pancytopenic, hypercalcemic, with marked splenomegaly on CT. PET-CT showed retroperitoneal and iliac chain lymphadenopathy along with mixed changes of osseous/marrow lesions with new lesions in the thoracic spine and left mid femur. There is a notable improvement in GL-ILD on CT chest while the patient is on prednisone. Renal biopsy showed acute tubular injury with increased deposition of calcium phosphate, along with moderate interstitial fibrosis and tubular atrophy with mild fibrointimal thickening of arteries. No monoclonal protein detected in the serum, negative JC virus, BK virus, EBV, CMV, and HIV. Splenic biopsy showed B cell lymphoma with features of micronodular T cell/histiocyte-rich large B cell lymphoma of the spleen. Patient initiated on rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone treatment protocol. Discussion BACH2 is a regulator of T and B cell differentiation and maturation. The effect of BACH2 on T cells involves limiting the differentiation of regulatory T (Treg) cells, which aid in preventing autoimmunity. BACH2 mutations have been described in the literature in patients with CVID and autoimmunity, such as ulcerative colitis. Lymphoma can cause hypercalcemia, which can lead to acute kidney injury. This patient has a variant of uncertain significance in BACH2 with CADD 25.2, allele frequency 2. His clinical picture of CVID, acute kidney injury in the setting of hypercalcemia, and newfound B cell lymphoma of the spleen may be due to this variant of uncertain significance. Further studies need to be conducted to better understand this gene and its role in CVID and B cell lymphoma. Tabular data are included as downloadable supplement files.
A Collaborative Initiative to Improve Anaphylaxis Management in Utah Schools
Witt, Bryan , Wright, Benjamin L. , Witt, Bryan S, Wright, Benjamin L

Pediatrics | April 15, 2026 | Volume: 157 | Issue: 5 | Pages: No page available

10.1542/peds.2025-073978 | PMID 41980724 Get It

Food allergies are a significant public health concern in the United States. Fatality from food-induced anaphylaxis is associated with delayed administration of epinephrine. Utah children were at increased risk for school-related anaphylaxis due to a lack of school nurses, adequately trained staff, and a standardized approach to food allergy emergency management. In collaboration with the Utah School Nurses Association, the Utah Food Allergy Network, and the Utah Department of Health & Human Services, among other contributors, we aimed to accomplish the following goals: (1) develop and implement a web-based curriculum to train school staff to recognize and respond to anaphylaxis in school settings; (2) educate school officials on existing legal protections for layperson first responders; and (3) facilitate acquisition of unassigned epinephrine for use in schools through existing charitable pharmaceutical programs. From 2012 to 2023, our training program was completed 5759 times by individuals representing 421 Utah schools. The course was most frequently completed by teachers (n = 3006, 52.2%), office staff (n = 1480, 25.7%), and principals (n = 276, 4.8%). Since 2015, we have maintained an average year-to-year retention rate of greater than 68%. We observed a 245% increase in the number of schools with unassigned epinephrine. Due to this intervention, many Utah schools now prepare employees to administer epinephrine in the case of anaphylactic emergencies. Although school nurses play a significant role, their coverage is inadequate to meet the needs of all students at risk for anaphylaxis. Training volunteers to recognize and respond to anaphylaxis in school settings is needed to reduce delays in treatment and improve outcomes.
A randomized, double-blind, placebo-controlled trial of soluble corn fiber supplementation for children with asthma
Rank, Matthew A. , Barroso, Daisy L., Conn, Kathryn A, Pecak, Melissa, Scandura, Matthew, Hirsch, Allyson H., Gu, Haiwei, Shearer, Heather L. , Johnson, Darcy, Argel, Natalia, Bauer, Cindy S., Williams, S.N., Woodward, James, Cope, Emily K. , Wright, Benjamin L. , Wright, Benjamin L , Gu, Haiwei , Whisner, Corrie Marie , Shearer, Heather, Woodward, James

Frontiers in Allergy | January 21, 2026 | Volume: 6 | Issue: No issue available | Pages: No page available

10.3389/falgy.2025.1707834 | PMID 41647190 Get It

Introduction Asthma is a multifactorial disease influenced by genetic and environmental factors, including diet. The gut microbiome contributes to airway inflammation via the gut-lung axis, partly through production of short chain fatty acids (SCFAs) from bacterial fermentation of dietary fiber. We hypothesized that dietary fiber supplementation could modulate the gut microbiome and increase SCFAs in children with asthma. Methods This is a double-blind, placebo-controlled trial of children who were randomized to consume 12 g of soluble corn fiber (SCF) as a supplement to their usual daily diet (50% the recommended daily fiber intake) or placebo for 4–6 weeks ( clinicaltrials.gov NCT03673618). Dietary surveys, asthma symptom questionnaires, fecal, blood and nasal samples were collected before and after the intervention period to quantify fiber intake, asthma control, nasal and gut microbiome, and serum short chain fatty acids (SCFAs). Results Of the 20 children enrolled, 15 completed the intervention with an average adherence rate of 83%. SCFA concentrations and gut microbiome changes varied by individual and treatment group. No significant differences in gut or nasal alpha or beta diversity were observed between groups post-intervention. However, differential abundance analysis showed a trend toward increased Bifidobacterium in the SCF group compared to placebo (ANCOM-BC p = 0.0004, FDR q = 0.073). Discussion Supplementation of 50% of recommended daily fiber intake had minimal impact on asthma symptoms, the microbiome, or SCFA levels. Future studies should consider higher fiber doses, different fiber types, or targeting individuals with low baseline fiber intake to account for observed variability in microbiome and SCFA responses. Clinical Trial Registration https://clinicaltrials.gov/study/NCT03673618 , identifier NCT03673618.
Mitochondrial dysfunction drives basal cell hyperplasia in eosinophilic oesophagitis
Morimoto, Masaki , Kawasaki, Kento , McNamee, Niamh , Shimonosono, Rieko, Shimonosono, Masataka , Matsuura, Norihiro, Tomita, Yasuto, Hirose, Wataru , Teranishi, Ryugo , Itami, Takefumi, Guha, Manti , Rajagopalan, Pavithra, Martin, Cecilia , Golden, Hailey, Dhakal, Diya, Wilkins, Benjamin J. , Wangensteen, Kirk J. , Pomenti, Sydney , Katzka, David A. , Que, Jianwen , Whelan, Kelly A. , Muir, Amanda B. , Kita, Hirohito , Wright, Benjamin L. , Doyle, Alfred D. , Teranishi, Ryugo , Abrams, Julian A , Katzka, D A , Wright, Benjamin L , Sachdeva, Uma M , Kita, H , Wangensteen, Kirk J , Que, Jianwen , Flashner, Samuel , Matsuura, Norihiro , Hirose, Wataru, Itami, Takefumi, Golden, Hailey, Klein–Szanto, Andres J. , Nakagawa, Hiroshi

Gut | July 23, 2025 | Volume: 74 | Issue: 10 | Pages: 1571-1588

10.1136/gutjnl-2024-334561 | PMID 40701793 Get It

Background Eosinophilic oesophagitis (EoE) is a food allergen-induced inflammatory disorder characterised by interleukin (IL)-13-mediated oesophageal inflammation and epithelial basal cell hyperplasia (BCH). The role of mitochondria in EoE pathogenesis remains elusive. Design Prompted by single cell transcriptomics data, we interrogated the role of mitochondria in EoE pathobiology using patient biopsies, EoE-mouse models and oesophageal epithelial cells grown in monolayer and three-dimensional (3D) organoid cultures treated with EoE-relevant cytokines. 3D organoids and EoE-bearing mice were treated with omeprazole—a proton-pump inhibitor used as first-line EoE therapy. We performed CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) interference in mouse organoids to identify the key mitochondrial regulatory genes whose depletion may lead to BCH. We analysed mitochondrial membrane potential, mass and superoxide production by flow cytometry, cellular oxygen consumption by respirometry, mitochondrial structures and perturbation of cellular energy homeostasis by immunoblotting. Results Mitochondrial dysfunction appeared to be a hallmark of EoE-related BCH where mitochondrial structural damage was associated with impaired oxidative respiratory capacity, elevation of mitochondrial superoxide and decreased adenosine triphosphate (ATP) production, as corroborated by activation of the adenosine monophosphate (AMP) -activated protein kinase and suppression of mammalian target-of-rapamycin signalling. Depletion of PGC1A, the master regulator of mitochondria biogenesis, recapitulated EoE-related BCH, suggesting that mitochondrial dysfunction drives BCH. Further, omeprazole alleviated mitochondrial damage and dysfunction in EoE-related BCH modelled in mice and patient-derived organoids. Conclusion Mitochondrial dysfunction is tightly linked to perturbation of redox homeostasis in EoE-related BCH, which is promoted by IL-13 and reversible with omeprazole treatment.
Unmasking the Culprits in Eosinophilic Esophagitis Pathogenesis
Wright, Benjamin L. , Wright, Benjamin L

New England Journal of Medicine | June 26, 2024 | Volume: 390 | Issue: 24 | Pages: 2321-2322

10.1056/nejme2404990 | PMID 38924736 Get It

Enhancing diversity, equity, inclusion, and accessibility in eosinophilic gastrointestinal disease research: the consortium for eosinophilic gastrointestinal disease researchers’ journey
Chehade, Mirna , Furuta, Glenn T. , Abonia, J. Pablo , Aceves, Seema S. , Bose, Paroma , Dellon, Evan S. , Eickel, Grant, Gupta, Sandeep K. , Hiremath, Girish , Howard, Amari, Kesh, Susamita, Khoury, Paneez , Kocher, Kendra, Kodroff, Ellyn, Kyle, Shay, Mak, NaDea , McCoy, D. E., Mehta, Pooja , Menard‐Katcher, Paul , Paliana, Ally, Sable, Kathleen, Schmitt, Cara, Scott, Melissa, Strobel, Mary Jo, Zicarelli, Amy, Muir, Amanda B. , Wright, Benjamin L. , Bailey, Dominique D., Wright, Benjamin L , Klion, Amy D. , Collins, Margaret H. , Davis, Carla McGuire , Falk, Gary W. , Jensen, Elizabeth T. , McCoy, Dawn, Mukkada, Vincent A. , Rothenberg, Marc E. , Spergel, Jonathan M. , Wechsler, Joshua B , Yang, Guang‐Yu

Therapeutic Advances in Rare Disease | August 14, 2023 | Volume: 4 | Issue: No issue available | Pages: No page available

10.1177/26330040231180895 | PMID 37588777 Get It

In response to the social inequities that exist in health care, the NIH-funded Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) recently formed a diversity committee to examine systemic racism and implicit bias in the care and research of eosinophilic gastrointestinal diseases (EGIDs). Herein, we describe our process, highlighting milestones and issues addressed since the committee’s inception, which we hope will inspire other researchers to enhance diversity, equity, inclusion, and accessibility (DEIA) in their fields. Our journey began by establishing mission and vision statements to define the purpose of the committee. Regular discussion of diversity-related topics was incorporated into existing meetings and web-based materials were shared. This was followed by educational initiatives, including establishing a library of relevant publications and a speaker series to address DEIA topics. We then established a research agenda focused on the following actionable items: (1) to define what is known about the demographics of EGIDs by systematic review of population-based studies; (2) to develop a practical tool for reporting participant demographics to reduce bias in EGID literature; (3) to examine health disparities in the care of individuals with eosinophilic esophagitis who present to the emergency department with an esophageal food impaction; (4) to examine how access to a gastroenterologist affects the conclusions of published research examining the prevalence of pediatric eosinophilic esophagitis; and (5) to develop a model for examining the dimensions of diversity, and provide a framework for CEGIR’s ongoing projects and data capture. In addition to promoting consciousness of DEIA, this initiative has fostered inclusivity among CEGIR members and will continue to inspire positive changes in EGID care and research.
Management and outcome of COVID-19 in CTLA-4 insufficiency
Ochoa, Sebastian , Abers, Michael S. , Rosen, Lindsey B. , Rump, Amy, Howe, Katherine , Lieberman, Phil , Wright, Benjamin L. , Suez, Daniel, Krausz, Máté , Grimbacher, Bodo , Uzel, Gülbû , Wright, Benjamin L , Lionakis, Michail S.

Blood Advances | July 5, 2023 | Volume: 7 | Issue: 19 | Pages: 5743-5751

10.1182/bloodadvances.2023010105 | PMID 37406177 Get It

Abstract Despite the high incidence of COVID-19 worldwide, clinical experience with severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) in inborn errors of immunity remains limited. Recent studies have shown that patients with defects in type 1 interferon (IFN)-related pathways or those with autoantibodies against type 1 IFNs develop severe COVID-19. We reported the clinical course of 22 patients with CTLA-4 insufficiency and COVID-19 and retrospectively examined autoantibodies against type 1 IFNs at baseline. Data were obtained from the patient interviews and chart reviews. Screening for anti-IFN autoantibodies was performed using a multiplex particle-based assay. Student t test, Mann Whitney, analysis of variance, or χ2 tests were used where appropriate. Twenty-two patients aged from 8 months to 54 years, with genetically confirmed CLTA-4 insufficiency, developed COVID-19 from 2020 to 2022. The most common symptoms were fever, cough, and nasal congestion, and the median duration of illness was 7.5 days. Twenty patients (91%) developed mild COVID-19 and were treated as outpatients. Two patients were hospitalized because of COVID-19 pneumonia but did not require mechanical ventilation. Ten (45%) patients were vaccinated at the time of their first COVID-19 infection. Eleven patients received outpatient treatment with monoclonal antibodies against the SARS-CoV-2 spike protein. During the study period, 17 patients were vaccinated against SARS-CoV-2, with no severe vaccine-related adverse effects. Although median anti-S titers following vaccination or infection were lower in patients receiving immunoglobulin replacement therapy (IGRT) (349 IU/dL) than in those not receiving IGRT (2594 IU/dL; P = .15); 3 of 9 patients on IGRT developed titers &gt;2000 IU/dL. All patients tested negative for autoantibodies against IFN-α, IFN-β, and IFN-ω at baseline. Most patients with CTLA-4 insufficiency and COVID-19 had nonsevere disease, lacked autoantibodies against type 1 IFNs, and tolerated messenger RNA vaccines with few adverse effects. Whether our findings can be extrapolated to patients receiving CTLA-4-targeting checkpoint inhibitors requires further studies.
Eosinophil Peroxidase Staining Enhances the Diagnostic Utility of the Cytosponge in Eosinophilic Esophagitis
Masuda, Mia Y. , Barshow, Suzanne , Garg, Shipra , Putikova, Arina, LeSuer, William E., Alexander, Jeffrey A. , Katzka, David A. , Dellon, Evan S. , Kita, Hirohito , Horsley‐Silva, Jennifer L. , Doyle, Alfred D. , Wright, Benjamin L. , Kita, H , Wright, Benjamin L

Clinical and Translational Gastroenterology | September 22, 2022 | Volume: 13 | Issue: 11 | Pages: e00534

10.14309/ctg.0000000000000534 | PMID 36137185 Get It

INTRODUCTION: We aimed to assess the diagnostic utility of eosinophil peroxidase (EPX) staining on Cytosponge (CS) samples in eosinophilic esophagitis (EoE). METHODS: Esophageal biopsy (BX) samples from adult subjects with EoE were assessed using peak eosinophils per high-power field (eos/hpf), EPX, and the EoE histologic scoring system. EPX staining and eos/hpf were compared (BX vs CS). RESULTS: CS EPX positivity correlated with eos/hpf (CS [ r = 0.82, P < 0.0001]; BX [ r = 0.65, P < 0.0001]) and EoE histologic scoring system (grade [ r = 0.62, P < 0.00001]; stage [ r = 0.61, P < 0.0001]). CS EPX identified subjects with active EoE (area under the curve = 0.86, P < 0.0001). DISCUSSION: The correlation of CS EPX with eosinophilic inflammation and histologic disease severity supports its diagnostic utility in EoE.